Does Semaglutide have an impact on non-diabetic individuals with overweight or obesity?
Unlocking Cardiovascular Benefits: Semaglutide’s Impact on Non-Diabetic Individuals with Overweight or Obesity In a groundbreaking study known as the SELECT Trial, researchers, led by Michael Lincoff, Kirstine Brown-Frandsen, and Helen M Colhoun, delved into the potential cardiovascular benefits of semaglutide, a glucagon-like peptide-1 receptor agonist. Unlike previous investigations that focused on diabetic patients, this trial […]
